Payment overview · 2025
General Payments
$1,859.64
88 reported records · 20 companies
Healthcare provider profile · identity verified
Soo Woong Kang
Allopathic & Osteopathic Physicians|Internal Medicine · BUENA PARK, CA · NPI 1164577706
Verified facts
What the public records show
CMS Open Payments records show Soo Woong Kang received $1,859.64 in general payments during 2025 across 88 reported records.
Ardelyx, Inc. accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Farxiga, Flector, Gemtesa, Jardiance, Kerendia, Licart, Linzess, Mounjaro, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 1020 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 702 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Viberzi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 591 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Nexium by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 348 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Trelegy Ellipta by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Flector as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Flector by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Licart as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Licart by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 702 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $237.10 | 12.8% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $165.73 | 8.9% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $162.65 | 8.8% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $158.67 | 8.5% | 8 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $142.56 | 7.7% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $140.13 | 7.5% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $124.22 | 6.7% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $109.28 | 5.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.02 | 5.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.08 | 5.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.99 | 4.4% | 4 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $55.82 | 3.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.48 | 2.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.27 | 2.6% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $43.94 | 2.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.92 | 2.1% | 2 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $29.08 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.45 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.14 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.11 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,859.64 | 88 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $237.10 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $165.73 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $160.58 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $141.93 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $124.22 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $110.07 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $109.28 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.08 | 5 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $95.59 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $80.99 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.99 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $69.44 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $56.51 | 3 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $55.82 | 3 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $55.82 | 3 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $55.82 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.48 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.51 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.51 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.27 | 2 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $46.97 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.70 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $43.94 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $39.92 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.83 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 59 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 1020 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 591 | exact normalized | Medicare Part D |
| Flector flector |
2025 | Flector | 2024 | 271 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 130 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 330 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 348 | exact normalized | Medicare Part D |
| Licart licart |
2025 | Licart | 2024 | 87 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 702 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 303 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 172 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
1020 | 208 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
702 | 122 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
162 | 94 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
90 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
591 | 99 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
348 | 59 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
330 | 52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
59 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
78 | 53 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
172 | 31 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Flector open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Flector · 2024 Exact normalized brand match · 1 Part D row |
271 | 37 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Licart open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Licart · 2024 Exact normalized brand match · 1 Part D row |
87 | 13 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
702 | 122 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
330 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
303 | 51 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
130 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2777 | 559 |
| Losartan Potassium | Losartan Potassium | 2469 | 500 |
| Amlodipine Besylate | Amlodipine Besylate | 2410 | 460 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2410 | 497 |
| Vascepa | Icosapent Ethyl | 1792 | 241 |
| Metformin Hcl | Metformin Hcl | 1753 | 348 |
| Omeprazole | Omeprazole | 1268 | 353 |
| Creon | Lipase/Protease/Amylase | 1020 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1018 | 169 |
| Lidocaine | Lidocaine | 986 | 141 |
| Meloxicam | Meloxicam | 869 | 213 |
| Tamsulosin Hcl | Tamsulosin Hcl | 845 | 180 |
| Linzess | Linaclotide | 702 | 122 |
| Clopidogrel | Clopidogrel Bisulfate | 694 | 101 |
| Ibuprofen | Ibuprofen | 686 | 430 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 663 | 125 |
| Donepezil Hcl | Donepezil Hcl | 656 | 111 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 652 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 644 | 150 |
| Alendronate Sodium | Alendronate Sodium | 624 | 135 |
| Celecoxib | Celecoxib | 606 | 143 |
| Farxiga | Dapagliflozin Propanediol | 591 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 519 | 97 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 502 | 193 |
| Diclofenac Sodium | Diclofenac Sodium | 499 | 111 |
| Gabapentin | Gabapentin | 479 | 101 |
| Glimepiride | Glimepiride | 477 | 72 |
| Azithromycin | Azithromycin | 474 | 355 |
| Hydrochlorothiazide | Hydrochlorothiazide | 452 | 83 |
| Glipizide | Glipizide | 402 | 80 |
| Lovastatin | Lovastatin | 362 | 65 |
| Januvia | Sitagliptin Phosphate | 354 | 55 |
| Kerendia | Finerenone | 348 | 59 |
| Pioglitazone Hcl | Pioglitazone Hcl | 341 | 69 |
| Tradjenta | Linagliptin | 335 | 40 |
| Jardiance | Empagliflozin | 330 | 52 |
| Ketoconazole | Ketoconazole | 329 | 66 |
| Simvastatin | Simvastatin | 328 | 66 |
| Finasteride | Finasteride | 321 | 68 |
| Atenolol | Atenolol | 305 | 62 |
| Rybelsus | Semaglutide | 303 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 283 | 84 |
| Hydralazine Hcl | Hydralazine Hcl | 276 | 42 |
| Flector | Diclofenac Epolamine | 271 | 37 |
| Icosapent Ethyl | Icosapent Ethyl | 271 | 76 |
| Memantine Hcl | Memantine Hcl | 264 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 251 | 50 |
| Dexlansoprazole Dr | Dexlansoprazole | 247 | 38 |
| Montelukast Sodium | Montelukast Sodium | 247 | 46 |
| Diclofenac Epolamine | Diclofenac Epolamine | 244 | 48 |
| Lisinopril | Lisinopril | 244 | 51 |
| Nifedipine Er | Nifedipine | 238 | 42 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 224 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 69 |
| Metformin Hcl Er | Metformin Hcl | 207 | 46 |
| Ciclopirox | Ciclopirox | 195 | 54 |
| Zenpep | Lipase/Protease/Amylase | 195 | 31 |
| Famotidine | Famotidine | 191 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 190 | 52 |
| Clonidine Hcl | Clonidine Hcl | 178 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 176 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 172 | 31 |
| Ztlido | Lidocaine | 166 | 25 |
| Raloxifene Hcl | Raloxifene Hcl | 165 | 36 |
| Prolia | Denosumab | 162 | 94 |
| Fluocinonide | Fluocinonide | 158 | 46 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 158 | 19 |
| Furosemide | Furosemide | 153 | 40 |
| Megestrol Acetate | Megestrol Acetate | 153 | 41 |
| Sildenafil Citrate | Sildenafil Citrate | 153 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 148 | 33 |
| Tadalafil | Tadalafil | 145 | 27 |
| Carvedilol | Carvedilol | 142 | 27 |
| Trazodone Hcl | Trazodone Hcl | 141 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 138 | 22 |
| Sertraline Hcl | Sertraline Hcl | 138 | 30 |
| Potassium Chloride | Potassium Chloride | 137 | 38 |
| Ozempic | Semaglutide | 136 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 135 | 29 |
| Propylthiouracil | Propylthiouracil | 132 | 23 |
| Allopurinol | Allopurinol | 131 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 131 | 26 |
| Gemtesa | Vibegron | 130 | 19 |
| Dexilant | Dexlansoprazole | 129 | 25 |
| Mupirocin | Mupirocin | 122 | 51 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 120 | 101 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 117 | 29 |
| Myrbetriq | Mirabegron | 116 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 114 | 78 |
| Meclizine Hcl | Meclizine Hcl | 113 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 24 |
| Xarelto | Rivaroxaban | 105 | 16 |
| Tramadol Hcl | Tramadol Hcl | 104 | 27 |
| Benazepril Hcl | Benazepril Hcl | 103 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 101 | 34 |
| Metoclopramide Hcl | Metoclopramide Hcl | 99 | 41 |
| Mirtazapine | Mirtazapine | 99 | 23 |
| Procto-Med Hc | Hydrocortisone | 96 | 34 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 94 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 93 | 93 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 93 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 92 | 43 |
| Brilinta | Ticagrelor | 90 | 12 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 89 | 12 |
| Pregabalin | Pregabalin | 88 | 16 |
| Licart | Diclofenac Epolamine | 87 | 13 |
| Eliquis | Apixaban | 86 | 21 |
| Verapamil Er | Verapamil Hcl | 86 | 11 |
| Alprazolam | Alprazolam | 82 | 37 |
| Doxazosin Mesylate | Doxazosin Mesylate | 82 | 14 |
| Lactated Ringers | Ringer's Solution,lactated | 81 | 64 |
| Ezetimibe | Ezetimibe | 80 | 20 |
| Repatha Sureclick | Evolocumab | 80 | 12 |
| Telmisartan | Telmisartan | 80 | 15 |
| Clotrimazole | Clotrimazole | 79 | 27 |
| Restasis | Cyclosporine | 79 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 78 | 53 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 78 | suppressed |
| Ranolazine Er | Ranolazine | 77 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 19 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 75 | 46 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 72 | 17 |
| Memantine Hcl Er | Memantine Hcl | 71 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 22 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 65 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 62 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 45 |
| Nexium | Esomeprazole Magnesium | 60 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 59 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 59 | 59 |
| Cephalexin | Cephalexin | 59 | 51 |
| Invokana | Canagliflozin | 59 | suppressed |
| Gemfibrozil | Gemfibrozil | 58 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 11 |
| Nitroglycerin | Nitroglycerin | 56 | 17 |
| Glipizide Er | Glipizide | 55 | suppressed |
| Acyclovir | Acyclovir | 54 | 34 |
| Minoxidil | Minoxidil | 53 | 15 |
| Lansoprazole | Lansoprazole | 51 | 11 |
| Spironolactone | Spironolactone | 51 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 50 | 15 |
| Dutasteride | Dutasteride | 49 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 49 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 47 | 15 |
| Irbesartan | Irbesartan | 47 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 46 | 16 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 45 | 18 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 44 | 20 |
| Sucralfate | Sucralfate | 43 | 17 |
| Cilostazol | Cilostazol | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 31 |
| Famciclovir | Famciclovir | 39 | 26 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Entecavir | Entecavir | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 17 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 35 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 35 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 34 | suppressed |
| Felodipine Er | Felodipine | 34 | suppressed |
| Methimazole | Methimazole | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Sotalol | Sotalol Hcl | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 31 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | suppressed |
| Colchicine | Colchicine | 27 | 11 |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Benicar | Olmesartan Medoxomil | 26 | suppressed |
| Tacrolimus | Tacrolimus | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Praluent Pen | Alirocumab | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Enulose | Lactulose | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | 19 |
| Ursodiol | Ursodiol | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Viberzi | Eluxadoline | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Verapamil Hcl | Verapamil Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Bystolic | Nebivolol Hcl | 18 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 18 | 16 |
| Methocarbamol | Methocarbamol | 18 | 14 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 18 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | 11 |
| Edarbi | Azilsartan Medoxomil | 17 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | 17 |
| Vemlidy | Tenofovir Alafenamide | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Forteo | Teriparatide | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 15 | 15 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Amitiza | Lubiprostone | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Exelon | Rivastigmine | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Baclofen | Baclofen | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,859.64 · 88 records | Ardelyx, Inc. | AIRSUPRA, AREXVY, BREZTRI, CREON, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Flector, GEMTESA, GVOKE HYPOPEN, IBSRELA, INGREZZA, JARDIANCE, Kerendia, LINZESS, Licart, MOUNJARO, OTEZLA, Ozempic, PANCREAZE, QSYMIA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tirosint, VERQUVO, XIFAXAN, ZEPBOUND | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error